Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders
Conditions
Interventions
Intervention1: Intravenous Dexmedtomidine: This study will be conducted as prospective, double blinded, placebo controlled randomised trial. The test group will receive Dexmedetomidine (0.5 mcg/kg) as
Sponsors
Kasturba Medical College Manipal
Mathew Tom
Eligibility
Inclusion criteria
Inclusion criteria: 1. American Society of Anaesthesiologists Physical Status Classification I and II patients 2. Age between 18-65 undergoing ECT
Exclusion criteria
Exclusion criteria: 1. American Society of Anaesthesiologists Physical Status Classification III and IV patients 2. Patients with pre-existing liver disorder 3. Patients with pre-existing renal disorder 4. Patients with pre-existing cardiac disorder 5. Patients with heart rate less than 60 bpm 6. Patients with blood pressure less than 90/60 mm of Hg 7. Patients with organic brain disease 8. Patients who undergo ECT under sedation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| â?¢To compare the incidence of Post ECT delirium in patients receiving prophylactic Dexmedetomidine infusion with a control groupTimepoint: Begins at 10 minutes after seizure activity has ended. The patient will then be assessed for delirium up to a total of 5 times at an interval of 10 minutes. The heart rate & mean arterial pressure (MAP) of the patient will be monitored during Dexmedetomidine infusion and post ECT every 5 minutes up to 50 minutes. The delirium will be measured from 10 minutes after the ECT upto 50 minutes after ECT at an interval of 10 minutes each. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To compare the duration of Post ECT delirium in patients receiving prophylactic Dexmedetomidine infusion with a control groupTimepoint: Begins at 10 minutes after seizure activity has ended. The patient will then be assessed for delirium up to a total of 5 times at an interval of 10 minutes. It will be measured from 10 minutes after the ECT upto 50 minutes after ECT at an interval of 10 minutes each.;2. To compare the effect of prophylactic Dexmedetomidine infusion in controlling the hyperdynamic changes in patients receiving ECT with a control groupTimepoint: The heart rate & mean arterial pressure (MAP) of the patient will be monitored during Dexmedetomidine infusion & post ECT every 5 minutes up to 50 minutes post ECT.;3. To assess the adverse effects of Dexmedetomidine in the group of patients receiving prophylactic DexmedetomidineTimepoint: The heart rate & mean arterial pressure (MAP) of the patient will be monitored during Dexmedetomidine infusion & post ECT every 5 minutes up to 50 minutes post ECT. | — |
Countries
India
Contacts
Public ContactMathew Tom
Kasturba Medical College, Manipal
Outcome results
None listed